<DOC>
	<DOCNO>NCT02846298</DOCNO>
	<brief_summary>Since discovery streptomycin 1944 , aminoglycosides retain remarkable bactericidal activity vis-à-vis include aerobic gram-negative bacillus . Thus , synergistic effect beta-lactams rapid bactericidal many make unavoidable pathogen make cornerstone treatment patient severe sepsis state septic shock . This antibiotic exclusively parenteral administration . Their effectiveness concentration-dependent administer 30-minute infusion . Tolerance venous usually excellent . Their potential nephrotoxicity cochleovestibular toxicity require accurate monitoring antibiotic residual . Moreover fact effectiveness aminoglycosides concentration dependent , rate peak decisive . A first sub-therapeutic dose lead adaptively resistant bacteria compare aminoglycoside therefore increase Minimal Inhibitory Concentrations ( MIC ) . Many study conduct patient hospitalize intensive care , highlight underdoses aminoglycosides prescribe dosage consistent use non reanimated patient . Dr Moore show 89 ICU patient bacteremia gram-negative bacillus , relationship clinical course obtain whether therapeutic level first administration aminoglycosides . Thus , mortality patient whose antibiotic concentration peak subtherapeutic , amount 20.9 % 2.4 % concentration within therapeutic range . In context initial peak PK / PD ( Pharmacokinetic / Pharmacodynamic ) objectives namely Cmax / MIC ≥ 8-10 desirable , individualized therapeutic drug monitoring identification factor may cause concentration antibiotic sub-therapeutic peak seem necessary , patient majority increase volume distribution . In addition β-lactams glycopeptides , due increase volume distribution critically ill patient sepsis , evaluation serum 24 hour start treatment check PK / PD goal molecule achieve .</brief_summary>
	<brief_title>Evaluation Pharmacokinetic / Pharmacodynamic Data Interest Individualized Therapeutic Drug Monitoring Glycopeptides β-lactam-aminoglycoside ICU</brief_title>
	<detailed_description>Primary / secondary objective Investigators propose conduct study goal : - Evaluate rate patient efficacy endpoint PK / PD Cmax / MIC ≥ 8-10 reach first dose usual dos . - Compare 30-day mortality among patient subclinical first rate versus reach desire peak - Evaluate rate patient PK / PD efficiency target relate antibiotic reach : - Serum residual &gt; 4X MIC β-lactam rate continuous function β-lactam germ . - Serum 25 35 mg / L vancomycin continuously . - Assess factor associate obtain rate aminoglycoside subtherapeutic peak population critically ill patient . - Assess residual 12h injection anticipation residual dose 24 . Methodology : - Type Of study : - Prospective , single-center type professional practice evaluation - Expected duration study six month - Objective inclusion : 50 100 patient . Computing number patient include do via BioStaTGV software . - Description Of study ( accord recommendation ) : - Admission patient intensive care unit - Levy peak aminoglycoside 30min end 30 minute infusion first administration - Collection residual aminoglycoside + 12h 23h-30 24 hour injection . - Extraction residual H + 24h , 30 min injection β-lactam associate administer discontinuously without time constraint administration batchwise β-lactam vancomycin . - Routing unsettled frozen tube &lt; 2 hour collection - Reception registration levy laboratory assay anti-infective usual care recommend service - Determination aminoglycoside vancomycin immunoturbidimetric method ( Indiko PLUS ) - Β-lactam assay LC-MS - Rendering usual result ( result server consultation partial report PDF available patient 's medical record DXcare ) . - Director-post MIC aminoglycoside β-lactam vis-à-vis offend germ bacterial strain isolate document infection - Destruction Levies : levy retain use study . They destroy accordance rule good practice research laboratory . Data Monitoring support : Patient data collect computer CRF include clinical , biological microbiological data patient via patient 's medical record DXcare : demographic , weight , height , BMI , hydration status , kidney function , liver function , shock , chronic heart failure , malnutrition , hypoalbuminemia burn , cirrhosis , chronic rheumatic disease , antecedent , pregnancy , reason hospitalization , etiology sepsis motivate introduction aminoglycosides , β-lactam glycopeptide also associate treatment . The data collect help identify risk factor associate sub-therapeutic dosing aminoglycosides , β-lactam glycopeptide .</detailed_description>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<criteria>Age w &lt; 18 year old admit ICU unit aminoglycoside treatment severe infection prescribe Age le 18 year Treatment aminoglycoside label Patient non hospitalize intensive care</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Drug Monitoring</keyword>
	<keyword>ICU</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>antibiotic</keyword>
	<keyword>Glycopeptides</keyword>
	<keyword>β-lactam-aminoglycoside</keyword>
</DOC>